Skip to content

GLP-1 drugs list: every brand, its generic name and what it is approved for

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

What are GLP-1 medications used for? Their FDA labels list long-term weight reduction (Zepbound, Wegovy, Foundayo, Saxenda), type 2 diabetes (Mounjaro, Ozempic, Rybelsus, Trulicity), cardiovascular risk reduction (Wegovy, Ozempic, Rybelsus, Trulicity, Mounjaro), kidney risk reduction in type 2 diabetes (Ozempic injection), obstructive sleep apnea (Zepbound) and MASH (Wegovy injection).

Source: Eli Lilly

Key takeaways

  • Each brand has its own label. An approved use doesn't carry over to a brand sharing its molecule.
  • Ozempic and Mounjaro have no weight reduction indication. Wegovy and Zepbound, which share their molecules, do.
  • Ask your prescriber which approved use your prescription is written for, in the label's words.
  • Give that use to your insurer or Part D plan, because plans decide coverage based on the indication.
  • Retatrutide and CagriSema are not FDA-approved for anything.

“GLP-1” gets used as a catch-all for eight brand-name medicines, and they don’t all treat the same things. The full GLP-1 drugs list we cover is Zepbound and Mounjaro (tirzepatide), Wegovy, Ozempic and Rybelsus (semaglutide), Foundayo (orforglipron), Saxenda (liraglutide) and Trulicity (dulaglutide). Some are approved for weight, some for type 2 diabetes, and a few carry extra uses for the heart, the kidneys, sleep apnea or the liver. Two pairs of brands share a molecule but have different labels. This page lists every approved use by condition, in the wording of the FDA labels on DailyMed.

GLP-1 drugs list: brand names and generic names

These are the eight FDA-approved GLP-1 medications, with the generic name (the active ingredient) behind each brand, how it’s taken, who makes it and the main approved uses. Retatrutide and CagriSema are still in development and aren’t on the list. The medicines in development page covers them.

Brand name Generic name How it’s taken Maker Approved for
Zepbound tirzepatide Weekly injection Lilly Weight reduction, obstructive sleep apnea
Mounjaro tirzepatide Weekly injection Lilly Type 2 diabetes, heart risk in type 2 diabetes
Wegovy semaglutide Weekly injection or daily tablet Novo Nordisk Weight reduction, heart risk, MASH (injection only)
Ozempic semaglutide Weekly injection or daily tablet Novo Nordisk Type 2 diabetes, heart risk, kidney risk (injection only)
Rybelsus semaglutide Daily tablet Novo Nordisk Type 2 diabetes, heart risk
Foundayo orforglipron Daily tablet Lilly Weight reduction
Saxenda liraglutide Daily injection Novo Nordisk Weight reduction
Trulicity dulaglutide Weekly injection Lilly Type 2 diabetes, heart risk

So there are five generic names behind the eight brands. Tirzepatide and semaglutide are each sold under more than one brand, with a different label for each. The sections below give every approved use in the labels’ own words.

The use on your prescription isn’t a technicality. It decides which brand your prescriber writes, whether your insurer or Medicare will pay, and what price you face if they won’t. The cheapest path tool starts from that question.

Which GLP-1s are approved for weight loss?

Four medicines carry an indication (an FDA-approved use) to reduce excess body weight and keep the weight off long term.

  • Zepbound (tirzepatide, weekly injection). Adults with obesity, or overweight with at least one weight-related comorbid condition, meaning a health problem linked to weight.
  • Wegovy (semaglutide, weekly injection or daily tablet). The injection is approved for adults and pediatric patients aged 12 years and older with obesity, and for adults with overweight and at least one weight-related comorbid condition. The tablets are approved for adults with obesity, and adults with overweight and at least one weight-related comorbid condition.
  • Foundayo (orforglipron, daily tablet). Adults with obesity, or overweight with at least one weight-related comorbid condition.
  • Saxenda (liraglutide, daily injection). Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, and adults with overweight and at least one weight-related comorbid condition.

The labels don’t present these as treatments on their own. The Zepbound and Foundayo labels say to use the medicine with a reduced-calorie diet and more physical activity. The nutrition page covers what the labels say about diet.

Which GLP-1s are approved for type 2 diabetes?

Four medicines are approved, alongside diet and exercise, to improve glycemic control (blood sugar control) in type 2 diabetes.

  • Mounjaro (tirzepatide, weekly injection). Adults and pediatric patients 10 years of age and older.
  • Ozempic (semaglutide, weekly injection or daily tablet). Adults.
  • Rybelsus (semaglutide, daily tablet). Adults.
  • Trulicity (dulaglutide, weekly injection). Adults and pediatric patients 10 years of age and older.

None of the four weight-management brands lists glycemic control as an approved use. Foundayo is not approved for type 2 diabetes. Lilly has since submitted Foundayo to FDA for type 2 diabetes, but a submission is not an approval. The type 2 diabetes page goes through each label.

Which GLP-1s are approved to reduce heart risk?

Five medicines carry an indication to reduce the risk of major adverse cardiovascular events, often shortened to MACE. The groups of people each label covers are different, and those differences matter for coverage.

  • Wegovy (injection and tablets). Adults with established cardiovascular disease and either obesity or overweight. Of the eight medicines, this is the only cardiovascular indication that doesn’t require type 2 diabetes.
  • Ozempic injection. Adults with type 2 diabetes and established cardiovascular disease.
  • Ozempic tablets and Rybelsus. Adults with type 2 diabetes who are at high risk for these events.
  • Trulicity. Adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
  • Mounjaro. Adults with type 2 diabetes who are at high risk for these events.

Each one rests on a different trial. In the Wegovy cardiovascular outcomes trial of 17,604 adults, the estimated hazard ratio for a first major event was 0.80 against placebo. A hazard ratio below 1 means fewer events than in the comparison group. In SUSTAIN 6, the Ozempic figure was 0.74 against placebo. Mounjaro’s trial compared it with dulaglutide, not placebo. It was non-inferior, meaning not worse by a set margin, and the label says superiority to dulaglutide was not established. These are separate trials in different people, so you can’t rank them against each other. The heart disease page has the detail.

Which GLP-1 is approved for kidney disease?

One. Ozempic injection is approved to reduce the risk of sustained eGFR decline (a lasting drop in kidney function), end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. In the FLOW trial of 3,533 patients, the label reports that Ozempic 1 mg was superior to placebo on the main combined kidney endpoint, with a hazard ratio of 0.76 over a median of 41 months. The approval is for the injection, not Ozempic tablets.

Which GLP-1 is approved for sleep apnea?

Zepbound is approved for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. In the label’s two 52-week sleep apnea studies, body weight changed by -17.7% and -19.6% with Zepbound, against -1.6% and -2.3% with placebo. None of the other seven medicines has a sleep apnea indication. See Zepbound for sleep apnea.

Which GLP-1 is approved for MASH?

Wegovy injection is approved, under accelerated approval, to treat noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease with inflammation) with moderate to advanced liver fibrosis, stages F2 to F3, in adults. At week 72 in the label trial, 63% of patients on Wegovy injection versus 34% on placebo had resolution of steatohepatitis without worsening of fibrosis. The approval doesn’t extend to Wegovy tablets. See Wegovy for MASH.

Same molecule, different brand: does it matter?

Yes. Three brands contain semaglutide (Wegovy, Ozempic and Rybelsus) and two contain tirzepatide (Zepbound and Mounjaro). Each brand has its own label, its own approved uses, its own strengths and its own price programs. An approved use on one label doesn’t transfer to the other brand. Ozempic has no weight reduction indication, and Wegovy has no glycemic control indication.

The labels also warn against doubling up. The Zepbound label says using it together with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. The Wegovy label says the same of other semaglutide-containing products and any other GLP-1 receptor agonist. The Saxenda label says it of other liraglutide-containing products, and the Foundayo label of another GLP-1 receptor agonist.

Whether a prescriber uses a medicine outside its labeled uses is a clinical decision we don’t cover. This site reports approved uses only.

Are GLP-1s approved for children and teenagers?

Only on some labels, and only for some uses.

  • Weight reduction, age 12 and older with obesity: Wegovy injection and Saxenda (Saxenda with body weight greater than 60 kg).
  • Type 2 diabetes, age 10 and older: Mounjaro and Trulicity. Their labels say safety and effectiveness have not been established in pediatric patients less than 10 years of age.
  • Not established in pediatric patients: Zepbound and Foundayo. The Saxenda label adds that its safety and effectiveness in pediatric patients with type 2 diabetes have not been established.

Why does the approved use decide who pays?

Coverage rules follow the use. Medicare shows this most clearly.

The Part D law excludes “agents when used for anorexia, weight loss, or weight gain.” Under CMS policy, an anti-obesity medicine can be covered in Part D only when it’s used for another medically accepted indication. CMS says type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic MASH with moderate to advanced liver scarring are indications eligible for Part D coverage. It names Wegovy for cardiovascular risk reduction and Zepbound for sleep apnea as examples of uses that can be covered.

So the same Wegovy pen can be excluded for one patient and covered for another, depending on the diagnosis on the prescription. For weight management alone, the Medicare route is the temporary GLP-1 Bridge, at a $50 copay for eligible enrollees. The Medicare guide explains both routes. States can choose whether Medicaid covers drugs used for weight loss, as the Medicaid page explains.

Commercial plans set their own rules. What holds everywhere is that a plan decides based on the indication. So before you call your insurer, ask your prescriber which approved use your prescription is written for.

If no coverage applies, manufacturer self-pay programs are tied to the brand too. Self-pay starts at $299 a month for Zepbound and $149 for the Wegovy pill. The cost guide and the without-insurance page list every price.

What is not approved

Uses and medicines still in trials are on the pipeline page. Retatrutide and CagriSema are not FDA-approved for anything. A use that shows up in a company press release isn’t an approved use until it’s on the label, and this page lists only what the labels say.

How to use this page

  1. Find your condition above and note which medicines list it.
  2. Ask your prescriber which approved use your prescription is for, in the label’s words.
  3. Give that use to your insurer or Part D plan when you ask about coverage.
  4. Run the cheapest path tool with your diagnosis and coverage to see the routes and prices.

Frequently asked questions

What conditions are GLP-1 medicines approved to treat?

Across the eight medicines we track, the FDA labels list six kinds of use. They are long-term weight reduction in obesity or overweight, glycemic control (blood sugar control) in type 2 diabetes, and reducing the risk of major adverse cardiovascular events. They also include reducing kidney and cardiovascular risk in type 2 diabetes with chronic kidney disease, moderate to severe obstructive sleep apnea in adults with obesity, and noncirrhotic MASH with moderate to advanced liver fibrosis.

Is Ozempic approved for weight loss?

No. Every approved use of Ozempic is in adults with type 2 diabetes: glycemic control (blood sugar control), cardiovascular risk reduction and, for the injection, kidney risk reduction in people with chronic kidney disease. Wegovy also contains semaglutide, and it's the brand with a weight reduction indication. Each has its own label and its own approved uses.

Is Mounjaro approved for weight loss?

No. Mounjaro is approved to improve glycemic control (blood sugar control) in adults and children 10 and older with type 2 diabetes. It's also approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk. Zepbound also contains tirzepatide, and it's the brand approved for long-term weight reduction and for obstructive sleep apnea.

Which GLP-1 is approved for sleep apnea?

Zepbound. Its label lists moderate to severe obstructive sleep apnea in adults with obesity as an approved use. None of the other seven medicines has a sleep apnea indication. CMS, the federal agency that runs Medicare, names this Zepbound use as one that Medicare Part D can cover.

Which GLP-1 is approved for heart disease?

Wegovy is approved to reduce the risk of major adverse cardiovascular events, such as heart attack and stroke, in adults with established cardiovascular disease and either obesity or overweight. Ozempic, Rybelsus, Trulicity and Mounjaro each carry a cardiovascular risk reduction indication for adults with type 2 diabetes. The wording differs from label to label.

Is any GLP-1 approved for fatty liver disease?

Yes, one. Wegovy injection is approved, under accelerated approval, to treat noncirrhotic MASH with moderate to advanced liver fibrosis (scarring), stages F2 to F3, in adults. The approval covers the injection, not Wegovy tablets. None of the other seven medicines lists a MASH indication.

Can teenagers take GLP-1 medicines?

Some labels include younger patients. Wegovy injection and Saxenda are approved for weight reduction in pediatric patients aged 12 and older with obesity (Saxenda also requires body weight above 60 kg). Mounjaro and Trulicity are approved for type 2 diabetes from age 10. The Zepbound and Foundayo labels say safety and effectiveness have not been established in pediatric patients.

Why does the reason for my prescription affect what I pay?

Because coverage rules follow the use, not the molecule. Medicare Part D excludes drugs when they're used for weight loss, but CMS says type 2 diabetes, sleep apnea, MASH and cardiovascular risk reduction are coverable. Savings cards and self-pay programs also have terms tied to the brand. The cheapest path tool starts from your diagnosis and your coverage.

Sources (27)

  1. 1.
    Eli Lilly: Eli Lilly and Company Form 10-Q for the quarter ended September 30, 2026
    “Submitted orforglipron for type 2 diabetes in the U.S. and Japan.”
  2. 2.
    FDA label (DailyMed): Wegovy prescribing information, section 14.1
    “WEGOVY injection significantly reduced the risk for first occurrence of MACE. The estimated hazard ratio (95% CI) was 0.80 (0.72, 0.90)”
  3. 3.
    FDA label (DailyMed): Ozempic prescribing information, section 14.2
    “OZEMPIC significantly reduced the occurrence of MACE. The estimated hazard ratio for time to first MACE was 0.74 (95% CI: 0.58, 0.95).”
  4. 4.
    FDA label (DailyMed): Ozempic prescribing information, section 14.3
    “OZEMPIC was superior to placebo in reducing the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥50%, sustained eGFR <15 mL/min/1.73m2, chronic renal replacement therapy, renal death, CV death (HR 0.76 [95% CI 0.66, 0.88], p=0.0003) as shown in Table 10 and Figure 7.”
  5. 5.
    FDA label (DailyMed): Mounjaro prescribing information, section 14.6
    “Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established.”
  6. 6.
    FDA label (DailyMed): Zepbound prescribing information, section 14.2, Table 9
    “Table 9: Changes in Apnea-Hypopnea Index (AHI), Hypoxic Burden, and Body Weight at Week 52 in Study 5 and Study 6. Body weight (kg) - % change from baseline: Study 5 Placebo N = 120: -1.6; Study 5 ZEPBOUND MTD (10 mg or 15 mg) N = 114: -17.7; Study 6 Placebo N = 114: -2.3; Study 6 ZEPBOUND MTD (10 mg or 15 mg) N = 119: -19.6”
  7. 7.
    FDA label (DailyMed): Wegovy prescribing information, section 14.4, Table 21
    “WEGOVY injection demonstrated improvement on these histopathology endpoints at Week 72 compared to placebo.”
  8. 8.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.”
  9. 9.
    FDA label (DailyMed): Foundayo Medication Guide (in the prescribing information)
    “Use FOUNDAYO with a reduced-calorie diet and increased physical activity.”
  10. 10.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  11. 11.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
  12. 12.
    FDA label (DailyMed): Saxenda prescribing information, section 1
    “SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  13. 13.
    FDA label (DailyMed): Foundayo prescribing information, section 1
    “Concomitant use with another GLP-1 receptor agonist is not recommended.”
  14. 14.
    FDA label (DailyMed): Zepbound prescribing information, section 8.4
    “The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.”
  15. 15.
    FDA label (DailyMed): Foundayo prescribing information, section 8.4
    “Safety and effectiveness of FOUNDAYO have not been established in pediatric patients.”
  16. 16.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.4
    “The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”
  17. 17.
    FDA label (DailyMed): Trulicity prescribing information, section 8.4
    “The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.”
  18. 18.
    FDA label (DailyMed): Saxenda prescribing information, section 1
    “The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established.”
  19. 19.
    Eli Lilly: Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
    “Based on these findings, as well as those from ACHIEVE-1 and ACHIEVE-4, Lilly plans to submit Foundayo for the treatment of type 2 diabetes to the U.S. FDA by the end of the second quarter under the Commissioner's National Priority Review Voucher. [...] Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity.”
  20. 20.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  21. 21.
    CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
    “Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
  22. 22.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  23. 23.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  24. 24.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “Currently, state Medicaid programs have discretion to cover the drugs or classes of drugs listed in section 1927(d)(2) of the Act, including “agents used for . . . weight loss . . .””
  25. 25.
  26. 26.
  27. 27.